ORGO (Organogenesis Holdings) ROCE % : 6.93% (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Organogenesis Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Organogenesis Holdings's annualized ROCE % for the quarter that ended in Sep. 2024 was 6.93%.

Organogenesis Holdings ROCE % Historical Data

The historical data trend for Organogenesis Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organogenesis Holdings ROCE % Chart

Organogenesis Holdings Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-22.03

15.17

24.14

6.07

3.34

Organogenesis Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															8.53	-1.36	-4.06	-15.19	6.93

Organogenesis Holdings ROCE % Calculation

Organogenesis Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	12.582	/	( ( (449.359 - 75.023)	+	(460.025 - 80.509) )	/ 2 )
	=	12.582	/	( (374.336	+	379.516)	/ 2 )
	=	12.582	/	376.926
	=	3.34 %

Organogenesis Holdings's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	25.176	/	( ( (443.163 - 85.727)	+	(446.296 - 77.281) )	/ 2 )
	=	25.176	/	( ( 357.436	+	369.015 )	/ 2 )
	=	25.176	/	363.2255
	=	6.93 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Organogenesis Holdings (NAS:ORGO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Organogenesis Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Organogenesis Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Organogenesis Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organogenesis Holdings Inc (NAS:ORGO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

2PQ:Germany

Address

85 Dan Road, Canton, MA, USA, 02021

Website

https://www.organogenesis.com

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. It has single operating segment which has regenerative medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.

Executives

Albert Erani	10 percent owner	150 DAN ROAD, 150 DAN ROAD, CANTON MA 01002
Michael W Katz	10 percent owner
Arthur S Leibowitz	director	139 SOUNDVIEW DRIVE, PORT WASHINGTON NY 11050
Michael Joseph Driscoll	director	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gary S. Gillheeney	director, officer: President and CEO	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gilberto Quintero	director	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Michele Ilene Korfin	director	17 STATE STREET, 7TH FLOOR, NEW YORK NY 10004
Antonio S. Montecalvo	officer: VP Health Policy & Contracting	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Jon L Giacomin	director	7000 CARDINAL PLACE, DUBLIN OH 43017
David Francisco	officer: Chief Financial Officer	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Red Holdings, Llc	10 percent owner	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Prathyusha Duraibabu	director	C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND CA 94804
Glenn H Nussdorf	director, 10 percent owner
Alan A. Ades	director, 10 percent owner	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gn 2016 Organo 10-year Grat U/a/d September 30, 2016	10 percent owner	C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021